12/4/2024

Janusmed kön och genus

Janusmed kön och genus – Isoptin

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Verapamil

Verapamil

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, Colditz GA, Hennekens CH, Willett WC. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US women: the nurses' health study. Cancer. 1998;83(9):2003-7.

  2. Mason RP. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?. J Am Coll Cardiol. 1999;34(7):1857-66.

  3. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Nørgaard M, McLaughlin JK et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat. 2006;97(3):231-6.

  4. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.

  5. Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB et al. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension. 2013;61:977-86.

  6. Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med. 2013;173(17):1629-37.

  7. Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos. 2006;27:329-34.

  8. Dilger K, Eckhardt K, Hofmann U, Kucher K, Mikus G, Eichelbaum M. Chronopharmacology of intravenous and oral modified release verapamil. Br J Clin Pharmacol. 1999;47:413-9.

  9. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther. 2000;68:286-92.

  10. Seeland U, Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol. 2012;214:211-36.

  11. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics?. Clin Pharmacokinet. 2002;41:329-42.

  12. Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, Schwartz JB. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40:219-30.

  13. Loeb ED, Diamond JA, Krakoff LR, Phillips RA. Sex difference in response of blood pressure to calcium antagonism in the treatment of moderate-to-severe hypertension. Blood Press Monit. 1999;4:209-12.

  14. White WB, Mehrotra DV, Black HR, Fakouhi TD. Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers) COER-Verapamil Study Group. Am J Cardiol. 1997;80:469-74.

  15. White WB, Johnson MF, Black HR, Elliott WJ, Sica DA. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. Am J Hypertens. 2001;14:1239-47.

  16. Isoptin retard (verapamil). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-05-11, cited 2020-10-13]

  17. Prisant LM, Weber M, Black HR. Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial. J Natl Med Assoc. 2005;97:377-83.

  18. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J. 1984;5:516-28.

  19. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol. 1990;66:779-85.

  20. Galatius-Jensen S, Launbjerg J, Mortensen LS, Hansen JF. Sex related differences in short and long-term prognosis after acute myocardial infarction: 10 year follow up of 3073 patients in database of first Danish Verapamil Infarction Trial. BMJ. 1996;313(7050):137-40.

  21. Sajadieh A, Storm HH, Hansen JF. Verapamil and risk of cancer in patients with coronary artery disease DAVIT Study Group Danish Verapamil Infarction Trial. Am J Cardiol. 1999;83:1419-22, A9.

  22. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.

  23. Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. J Electrocardiol. 2015;48:1081-7.

  24. Croog SH, Kong BW, Levine S, Weir MR, Baume RM, Saunders E. Hypertensive black men and women Quality of life and effects of antihypertensive medications Black Hypertension Quality of Life Multicenter Trial Group. Arch Intern Med. 1990;150:1733-41.

  25. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, Colditz GA, Hennekens CH, Willett WC. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US women: the nurses' health study. Cancer. 1998;83(9):2003-7.
  2. Mason RP. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?. J Am Coll Cardiol. 1999;34(7):1857-66.
  3. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Nørgaard M, McLaughlin JK et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat. 2006;97(3):231-6.
  4. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
  5. Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB et al. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Hypertension. 2013;61:977-86.
  6. Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years. JAMA Intern Med. 2013;173(17):1629-37.
  7. Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos. 2006;27:329-34.
  8. Dilger K, Eckhardt K, Hofmann U, Kucher K, Mikus G, Eichelbaum M. Chronopharmacology of intravenous and oral modified release verapamil. Br J Clin Pharmacol. 1999;47:413-9.
  9. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther. 2000;68:286-92.
  10. Seeland U, Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol. 2012;214:211-36.
  11. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics?. Clin Pharmacokinet. 2002;41:329-42.
  12. Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, Schwartz JB. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol. 2000;40:219-30.
  13. Loeb ED, Diamond JA, Krakoff LR, Phillips RA. Sex difference in response of blood pressure to calcium antagonism in the treatment of moderate-to-severe hypertension. Blood Press Monit. 1999;4:209-12.
  14. White WB, Mehrotra DV, Black HR, Fakouhi TD. Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers) COER-Verapamil Study Group. Am J Cardiol. 1997;80:469-74.
  15. White WB, Johnson MF, Black HR, Elliott WJ, Sica DA. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. Am J Hypertens. 2001;14:1239-47.
  16. Isoptin retard (verapamil). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2020-05-11, cited 2020-10-13]
  17. Prisant LM, Weber M, Black HR. Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the chrono trial. J Natl Med Assoc. 2005;97:377-83.
  18. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J. 1984;5:516-28.
  19. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol. 1990;66:779-85.
  20. Galatius-Jensen S, Launbjerg J, Mortensen LS, Hansen JF. Sex related differences in short and long-term prognosis after acute myocardial infarction: 10 year follow up of 3073 patients in database of first Danish Verapamil Infarction Trial. BMJ. 1996;313(7050):137-40.
  21. Sajadieh A, Storm HH, Hansen JF. Verapamil and risk of cancer in patients with coronary artery disease DAVIT Study Group Danish Verapamil Infarction Trial. Am J Cardiol. 1999;83:1419-22, A9.
  22. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.
  23. Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. J Electrocardiol. 2015;48:1081-7.
  24. Croog SH, Kong BW, Levine S, Weir MR, Baume RM, Saunders E. Hypertensive black men and women Quality of life and effects of antihypertensive medications Black Hypertension Quality of Life Multicenter Trial Group. Arch Intern Med. 1990;150:1733-41.
  25. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]